ANAVEX LIFE SCIENCES CORP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ANAVEX LIFE SCIENCES CORP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($46.38M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($43.00M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($47.51M) | Nov 25, 2025 |
| FY2023 | Sep 30, 2022 | ($47.98M) | Nov 27, 2023 |
| FY2023 | Sep 30, 2021 | ($37.91M) | Nov 27, 2023 |
| FY2022 | Sep 30, 2020 | ($26.28M) | Nov 28, 2022 |
| FY2020 | Sep 30, 2019 | ($26.29M) | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | ($17.25M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | ($13.46M) | Jan 25, 2019 |
| FY2018 | Sep 30, 2016 | ($14.74M) | Jan 25, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($51.41M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($52.88M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($55.76M) | Nov 25, 2025 |
| FY2023 | Sep 30, 2022 | ($50.99M) | Nov 27, 2023 |
| FY2023 | Sep 30, 2021 | ($42.00M) | Nov 27, 2023 |
| FY2022 | Sep 30, 2020 | ($31.09M) | Nov 28, 2022 |
| FY2014 | Sep 30, 2014 | ($2.97M) | Dec 29, 2014 |
| FY2014 | Sep 30, 2013 | ($2.14M) | Dec 29, 2014 |
| FY2013 | Sep 30, 2012 | ($4.32M) | Dec 30, 2013 |
| FY2012 | Sep 30, 2011 | ($6.18M) | Dec 31, 2012 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $37.59M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $41.84M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $43.72M | Nov 25, 2025 |
| FY2023 | Sep 30, 2022 | $37.92M | Nov 27, 2023 |
| FY2023 | Sep 30, 2021 | $32.98M | Nov 27, 2023 |
| FY2022 | Sep 30, 2020 | $25.23M | Nov 28, 2022 |
| FY2020 | Sep 30, 2019 | $22.26M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $13.34M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $10.67M | Jan 25, 2019 |
| FY2018 | Sep 30, 2016 | $7.25M | Jan 25, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $13.82M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $11.04M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $12.05M | Nov 25, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($39.04M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($30.81M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($27.79M) | Nov 25, 2025 |
| FY2023 | Sep 30, 2022 | ($24.24M) | Nov 27, 2023 |
| FY2023 | Sep 30, 2021 | ($30.38M) | Nov 27, 2023 |
| FY2022 | Sep 30, 2020 | ($21.29M) | Nov 28, 2022 |
| FY2020 | Sep 30, 2019 | ($18.53M) | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | ($12.58M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | ($9.02M) | Jan 25, 2019 |
| FY2018 | Sep 30, 2016 | ($9.24M) | Jan 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Sep 30, 2014 | $3.0K | Dec 14, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $103.82M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $135.57M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $154.39M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $152.71M | Nov 27, 2023 |
| FY2022 | Sep 30, 2021 | $161.62M | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | $34.54M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | $25.33M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $26.21M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $27.84M | Jan 25, 2019 |
| FY2017 | Sep 30, 2016 | $9.50M | Dec 11, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.95M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $15.30M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $12.53M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $10.21M | Nov 27, 2023 |
| FY2022 | Sep 30, 2021 | $10.80M | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | $7.31M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | $5.04M | Dec 28, 2020 |
| FY2017 | Sep 30, 2017 | $3.58M | Dec 11, 2017 |
| FY2017 | Sep 30, 2016 | $3.19M | Dec 11, 2017 |
| FY2016 | Sep 30, 2015 | $2.66M | Dec 14, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $94.87M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $120.26M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $141.85M | Nov 25, 2025 |
| FY2025 | Sep 30, 2022 | $142.49M | Nov 25, 2025 |
| FY2023 | Sep 30, 2021 | $150.82M | Nov 27, 2023 |
| FY2023 | Sep 30, 2020 | $27.24M | Nov 27, 2023 |
| FY2022 | Sep 30, 2019 | $20.29M | Nov 28, 2022 |
| FY2020 | Sep 30, 2018 | $22.32M | Dec 28, 2020 |
| FY2019 | Sep 30, 2017 | $25.88M | Dec 16, 2019 |
| FY2018 | Sep 30, 2016 | $6.31M | Jan 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($382.45M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($336.07M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | ($293.07M) | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | ($245.56M) | Nov 27, 2023 |
| FY2022 | Sep 30, 2021 | ($197.59M) | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | ($159.68M) | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | ($133.40M) | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | ($107.10M) | Dec 16, 2019 |
| FY2019 | Oct 2, 2017 | ($89.85M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | ($91.48M) | Jan 25, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $102.58M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $132.19M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $151.02M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | $149.16M | Nov 27, 2023 |
| FY2022 | Sep 30, 2021 | $152.11M | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | $29.25M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | $22.19M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $22.93M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $27.44M | Jan 25, 2019 |
| FY2018 | Sep 30, 2016 | $9.19M | Jan 25, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Sep 30, 2015 | $332 | Dec 14, 2016 |
| FY2015 | Sep 30, 2014 | $5.72M | Dec 29, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | 0 | Nov 25, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Nov 27, 2023 |
| FY2023 | Sep 30, 2021 | 0 | Nov 27, 2023 |
| FY2016 | Sep 30, 2016 | 0 | Dec 14, 2016 |
| FY2016 | Sep 30, 2015 | 0 | Dec 14, 2016 |
| FY2016 | Sep 30, 2014 | (1) | Dec 14, 2016 |
| FY2014 | Sep 30, 2013 | 0 | Dec 29, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | 0 | Nov 25, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Nov 27, 2023 |
| FY2023 | Sep 30, 2021 | 0 | Nov 27, 2023 |
| FY2016 | Sep 30, 2016 | 0 | Dec 14, 2016 |
| FY2016 | Sep 30, 2015 | 0 | Dec 14, 2016 |
| FY2016 | Sep 30, 2014 | (1) | Dec 14, 2016 |
| FY2014 | Sep 30, 2013 | 0 | Dec 29, 2014 |
| FY2013 | Sep 30, 2012 | 0 | Dec 30, 2013 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 86.67M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 84.80M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | 82.07M | Dec 23, 2024 |
| FY2023 | Sep 30, 2022 | 77.94M | Nov 27, 2023 |
| FY2022 | Sep 30, 2021 | 75.92M | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | 62.05M | Nov 24, 2021 |
| FY2020 | Sep 30, 2019 | 52.65M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | 45.93M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | 43.33M | Jan 25, 2019 |
| FY2017 | Sep 30, 2016 | 36.17M | Dec 11, 2017 |